Stockreport

Foghorn Therapeutics (FHTX): Forecast 28.8% Revenue Growth Challenges Ongoing Loss Narrative [Yahoo! Finance]

Foghorn Therapeutics Inc.  (FHTX) 
PDF five years and no positive EPS expected in the next three years. Despite the unprofitable streak, revenue is forecast to surge by 28.79% a year, far exceeding the US mar [Read more]